← Leaderboards
Ping-Ying Pan
Icahn School Of Medicine At Mount Sinai
$4,109,546
Attributed
$4,720,329
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $805.8K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,720,329 · 3
By mechanism
R01$4,720,329 · 3
Top collaborators
- Shu-Hsia Chen2 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Darrell J Irvine$37,519,809
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMediatingPreventLigandsMacrophageNeoplastic CellMyelogenousMyeloid CellsBaseRelapseExhibitsReceptorModalityMalignant NeoplasmsNeoplasm MetastasisRecurrenceOrthologous GeneImmunoglobulinsPhenotypeCellsLeukocytesLaboratoriesImmuneChemotherapy
Grant awards (12)
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity$610,783
R01 · FY2025 · CA
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity$610,783
R01 · FY2024 · CA
Novel therapy targeting refractory colon cancer$1
R01 · FY2019 · CA · contact PI
Novel therapy targeting refractory colon cancer$432,692
R01 · FY2018 · CA · contact PI
Novel therapy targeting refractory colon cancer$430,907
R01 · FY2017 · CA · contact PI
Novel therapy targeting refractory colon cancer$454,126
R01 · FY2016 · CA · contact PI
Novel therapy targeting refractory colon cancer$454,126
R01 · FY2015 · CA · contact PI
HSC Derived MDSC for the Prevention of GHVD Without Suppressing GvL$351,713
R01 · FY2015 · CA · contact PI
HSC Derived MDSC for the Prevention of GHVD Without Suppressing GvL$341,162
R01 · FY2014 · CA · contact PI
HSC Derived MDSC for the Prevention of GHVD Without Suppressing GvL$330,610
R01 · FY2013 · CA · contact PI
HSC Derived MDSC for the Prevention of GHVD Without Suppressing GvL$351,713
R01 · FY2012 · CA · contact PI
HSC Derived MDSC for the Prevention of GHVD Without Suppressing GvL$351,713
R01 · FY2011 · CA · contact PI